Attached files
file | filename |
---|---|
EX-10.1 - EX-10.1 - DUSA PHARMACEUTICALS INC | y84556exv10w1.htm |
8-K - FORM 8-K - DUSA PHARMACEUTICALS INC | y84556e8vk.htm |
EXHIBIT 99.1
For
release at 12:00 p.m.
Contacts:
Robert F. Doman, President & CEO 978-909-2216
Richard Christopher, VP Finance & CFO 978-909-2211
Chad Rubin, Investor Relations Contact, The Trout Group LLC 646-378-2947
Robert F. Doman, President & CEO 978-909-2216
Richard Christopher, VP Finance & CFO 978-909-2211
Chad Rubin, Investor Relations Contact, The Trout Group LLC 646-378-2947
DUSA Pharmaceuticals Announces
Slate of Nominees for Election to the Board of Directors
Slate of Nominees for Election to the Board of Directors
New nominees include Paul Hondros, Alfred Altomari and David Wurzer
WILMINGTON, Mass. May 13, 2010 DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA),
a dermatology company that is developing and marketing Levulan® Photodynamic Therapy
(PDT) and other products focused on patients with common skin conditions, today announced that its
Annual Meeting of Shareholders will be held on Thursday, July 29, 2010 at 11:00 AM at the Companys
offices at 25 Upton Drive, Wilmington, MA. The Company also reported that it has
nominated a slate of directors for election at the annual meeting, namely, Jay M. Haft, Esq.,
Chairman, Alfred Altomari, David M. Bartash, Alexander W. Casdin, Robert F. Doman, Paul Hondros,
Magnus Moliteus and David M. Wurzer. The nomination of David M. Wurzer is being made as a result of
the resolution of the Companys discussions with SRB Greenway Opportunity Fund, (QP), L.P. and SRB
Greenway Opportunity Fund, L.P. , and several affiliates (SRB Funds). A full copy of the
agreement with the SRB Funds dated May 13, 2010 will be filed as an exhibit to the Companys Form
8-K being filed contemporaneously with this announcement.
We are excited to propose such a strong slate of directors, which includes several new
nominees. We believe their experience, successful track records and demonstrated corporate
leadership will greatly benefit the Company and its shareholders, stated Robert Doman, President
and Chief Executive Officer.
Paul Hondros, 61, has over 30 years of investment industry experience and is the current President
and Chief Executive Officer of AlphaOne Capital Partners, LLC, and its affiliate companies. Prior
to his employment at AlphaOne Capital Partners, LLC which he founded in December of 2008, he was
the President and Chief Executive Officer of Gartmore Global Investments and President and Chief
Executive Officer of the Gartmore Group, a global asset management company, which oversaw $85
billion in assets. In 1998, he founded Villanova Capital, Inc., which operated until 2003, when it
was merged into Gartmore Investment Management plc. From 1990-1997 he was the President and Chief
Executive Officer of Fidelity Investments Institutional Services Company and also as the President
and Chief Executive Officer of its Individual Investors groups. Early in his career, Mr. Hondros
worked with SEI Investments, Inc., a global investment management, software, and mutual fund
services company, where he began his career as a computer programmer, eventually rising to
Executive Vice President of its Financial Services Division. Mr. Hondros is also the Chairman of
the Board of Trustees of St. Josephs University, from which he earned his bachelors degree in
history, and where he and Mrs. Hondros recently founded The Kinney Center for Autism Studies.
Alfred Altomari, 51, was Chief Executive Officer of Barrier Therapeutics, Inc. a specialty
pharmaceutical company focused in dermatology from April 2008, and a member of the Companys Board
of Directors from January 2008, until the sale of the company to GlaxoSmithKline plc in August
2008. He joined Barrier as Chief Commercial Officer in 2003 and became Chief Operating Officer in
2006. Prior to joining Barrier, he served in numerous executive roles in general management,
commercial operations, business development, product launch preparation and finance within Johnson
& Johnson from 1982 to 2003, including Vice President/Franchise Head of Ortho-McNeil
Pharmaceuticals Womens Health Care Franchise. He completed his undergraduate studies at Drexel
University earning a Bachelors of Science degree with a dual major in finance and accounting, and
subsequently received a Masters in Business Administration from Rider University. Mr. Altomari
currently serves as a member of the Board of Directors of Auxilium Pharmaceuticals Inc. and three
privately held companies. Mr. Altomari is also currently serving as a member of the advisory board
of Le Bow College, the Business School of Drexel University.
David M. Wurzer, 51, has served since November 2009 as the Managing Director, Investments of Connecticut
Innovations, the venture capital firm of the State of Connecticut. He served from September 1997 to
December 2007 as the Executive Vice President, Treasurer and Chief Financial Officer of CuraGen
Corporation, a biopharmaceutical development company, and from February 1994 until September 1997
as the Senior Vice President, Treasurer and Chief Financial Officer of Value Health, Inc. He
currently serves as a director of Strategic Diagnostics, Inc. He has a Bachelor of Business
Administration degree in Accounting from the University of Notre Dame.
Robert F. Doman remarked, On behalf of DUSAs Board and management team I want to sincerely thank
Richard Lufkin for his 18 years of dedicated service as a member of the Board, including many years
as the Chairman of the Audit Committee. Doman added, Similarly, we would like to thank John H.
Abeles, M.D. for his more than 15 years of service on the Board of Directors. We greatly appreciate
their contributions and unwavering commitment to the Company. Mr. Lufkin and Dr. Abeles will
continue to serve as directors until the 2010 Annual Meeting.
SECURITY HOLDERS ARE ADVISED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS RELATED TO THE
SOLICITATION OF PROXIES ON BEHALF OF THE COMPANY FOR USE AT THE 2010 ANNUAL MEETING WHEN THEY
BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING INFORMATION RELATING
TO THE NOMINEES. WHEN COMPLETED, A DEFINITIVE PROXY STATEMENT AND A FORM OF PROXY WILL BE
AVAILABLE TO SHAREHOLDERS OF THE COMPANY AT NO CHARGE AND WILL ALSO BE AVAILABLE AT NO CHARGE AT
THE WEBSITE OF THE SECURITIES AND EXCHANGE COMMISSION (THE SEC) AT http://www.sec.gov.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on
the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology
platform, and complementary dermatology products. Levulan® PDT is currently approved
for the treatment of minimally to moderately thick actinic keratoses of the face or scalp. DUSA
also markets other dermatology products, including ClindaReach®. DUSA is researching
the use of broad area Levulan® PDT to treat AKs and prevent squamous cell carcinomas in
immunosuppressed solid organ transplant recipients and is supporting research related to oral
leukoplakia in collaboration with the National Institutes of Health (NIH). DUSA is based in
Wilmington, Mass. Please visit our web site at www.dusapharma.com.
Except for historical information, this news release contains certain forward-looking statements
that represent our current expectations and beliefs concerning future events, and involve certain
known and unknown risk and uncertainties. These forward-looking statements relate to beliefs
concerning new nominees to our Board of Directors and continuing service of existing Board members.
These forward-looking statements are further qualified by important factors that could cause
actual results to differ materially from future results, performance or achievements expressed or
implied by those in the forward-looking statements made in this release. These factors include,
without limitation, reliance on third parties and other risks and uncertainties identified in
DUSAs Form 10-K for the year ended December 31, 2009.
###